Search results

Following on from the above about CA10 and MCT1/lactate: in whatever way CA10 can increase risk of ME/CFS, it's likely that the same mechanism would increase risk for chronic pain, since both conditions share a causal variant near CA10. So assuming that mechanism has something to do with...

Catalytically inactive carbonic anhydrase‐related proteins enhance transport of lactate by MCT1 Web | DOI | PMC | PDF | FEBS Open Bio | Open Access CA10 (also known as CARP X) can increase the rate at which the protein MCT1 transports lactate across the cell membrane. Somewhat interesting...

Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study Background A subset of individuals experience prolonged neurological and psychiatric symptoms following SARS-CoV-2 infection, a condition referred to as long...

I'm not sure how many of the participants had ME/CFS, but a few of the free text responses for negative effects in the supplementary file talk about crashes or something like a crash:

Transdiagnostic cognitive behavioral therapy for severe and persistent fatigue – a feasibility study in primary care Frank Svärdman, Conrad Samuelsson, Ludwig Franke Föyen, Anna Oremark, Anna Högfeldt, Jacob Andersson Emad, Douglas Sjöwall, Christian Rück, Erik Hedman-Lagerlöf, Hans Knoop, Elin...

There seem to be some mistakes with the percentages in that table. For "Headache", 73/141 = 51.8%, not 55.8%. For "Poor memory", 84/141 = 59.6%, not 9.6%. For "Visuo-spatial/balance/coordination, 92/141 = 65.2%, not 62.2%.

ME Research UK: "Could reaction times to 3D virtual reality tasks act as a biomarker for fatigue in ME/CFS?" 'Although this was a relatively small study, the results showed that when compared with those of healthy controls, reaction times of those with ME/CFS were significantly slower. It was...

Correspondence about this. I can't access the letter from Wyller et al, but the reply to it gives a good idea of what was said. Methodological considerations for interpreting a scoping review of pediatric long COVID biomarkers Joel Pradeepkumar Selvakumar, Vegard Bruun Bratholm Wyller Web | DOI...

Biomarkers of long COVID in children and young adults: a scoping review Bettina Camara, Danilo Buonsenso Abstract Following the SARS-CoV-2 pandemic, a significant percentage of people are now experiencing long-term symptoms, despite a continuing lack of concrete documentation of physiological...

This is on patients who have long COVID and ME/CFS. ME/CFS diagnosis seems to be based on the DePaul symptom questionnaire. I'm not sure if they also had to fulfill other criteria. Strikingly large difference between groups for anti-calcium sensing receptor (CaSR) antibodies: No...

Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation Stephanie L. Grach, Jaime Seltzer, Michael R. Mueller, Chris A. Aakre, Lasonya T. Natividad, Donna K. Lawson, Ravindra Ganesh, Ryan T. Hurt PURPOSE Myalgic...

Changes from preprint abstract. New additions in bold, removed parts are struck out.

Now published: Pathogenic IgG from long COVID patients with neurological sequelae triggers sensitive but not cognitive impairments upon transfer into mice Abstract Approximately 30% of long COVID patients still experience neurological symptoms (brain fog, pain, chronic fatigue) more than 4...

Now published: Symptom clusters in ME/CFS reflect distinct neuroimmune and autonomic pathophysiological mechanisms: a translational model Habermann-Horstmeier, Lotte; Horstmeier, Lukas M. Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem...

We could do that. These are the variants that passed the genome-wide significance threshold at this locus:

The GTEx project which is a very large study (in terms of funding and influence, but also sample size) meant to determine which variants are associated with gene expression. So probably fairly reliable.

It looks like that most significant result for BTN2A1 is based on the "raredmgmtr" model, which is defined as including variants that are: The REVEL paper says: So I'm not sure these variants are necessarily making the protein less functional. I would think that a missense variant could make...

DecodeME. They tested whether there is a shared variant that is both associated with ME/CFS and with BTN2A2 expression. It's described in the candidate genes document. Another finding: Yes, and there are more possibilities than just increased/decreased expression. A variant might slightly...

It's a significant variant on chromosome 6 with many genes in the area, so we can't be sure yet which gene it affects. DecodeME did not detect that the ME/CFS variant also affects expression of BTN2A1. (Though the risk allele was associated with decreased expression of BTN2A2.) That study...

It's mendelian randomization based, so they're doing something like looking at SNPs associated with expression of BTN2A1, and looking at the associations of those SNPs with disease in a different cohort to see if expression of the gene may be causal for the disease. And they found that increased...